Rezolve Ai to Announce Second Half and Full Year 2024 Financial Results on April 24, 2025 and Host a 2025 Business Update Conference Call on April 28, 2025
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce technology, announces that the Company will report second half and full year 2024 financial results on Thursday, April 24, 2025 after market close. Rezolve Ai's management team will then host a live conference call and webcast on Monday, April 28, 2025 at 8:30 a.m. ET to discuss the financial results and provide a year-to-date 2025 business update.
The live conference call and webcast can be found on Rezolve Ai's Investor Relations website at https://investor.rezolve.com/ or directly through the following link. Participants that would like to ask management a question will have the opportunity to pre-submit such questions to investors@rezolve.com.
Following the live call, a replay of the webcast will be available on the Company's Investor Relations website.
About Rezolve AiRezolve Ai (NASDAQ: RZLV) is an industry leader in AI-powered solutions, specializing in enhancing customer engagement, operational efficiency, and revenue growth. The Brain Suite delivers advanced tools that harness artificial intelligence to optimize processes, improve decision-making, and enable seamless digital experiences. For more information, visit www.rezolve.com.
Media ContactRezolve AiUrmee Khan - Global Head of Communicationsurmeekhan@rezolve.com+44 7576 094 040
Investor ContactCORE IR+15162222560investors@rezolve.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Golden Generation Travel Market Trends, Opportunity, and Forecasts to 2030: Key Players Like Hilton and Airbnb Lead the Charge in Reinventing Senior-Oriented Travel Experiences
The Golden Generation Travel Market offers lucrative opportunities by catering to retirees with disposable income, seeking enriching, comfortable, and adventure-filled travel experiences. Providers can capitalize on wellness travel trends, offering accessible, premium, and health-focused services tailored to seniors' evolving preferences. Golden Generation Travel Market Dublin, July 01, 2025 (GLOBE NEWSWIRE) -- The "Golden Generation Travel Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to Golden Generation Travel Market was valued at USD 8.74 Billion in 2024 and is expected to reach USD 14.84 Billion by 2030, rising at a CAGR of 9.28%. Growth is primarily fueled by a rising global retiree population, increased disposable incomes, and evolving lifestyle preferences among older adults. This demographic seeks comfort, enrichment, and adventure in their travel experiences, supported by advancements in travel planning technologies and improved global connectivity. Enhanced health awareness and the desire to maintain active lifestyles also drive demand for travel options tailored to the needs of seniors. With a growing appetite for meaningful experiences, the market presents ample opportunities for providers offering accessible, wellness-oriented, and premium travel services. Key Market Drivers: Increased Disposable Income and Financial Stability The financial independence and growing disposable income among individuals aged 55 and above serve as major catalysts for the Golden Generation Travel Market. Many seniors have accumulated substantial savings through pensions, investments, property appreciation, or inheritance. With fewer financial responsibilities such as child-rearing or mortgage payments, older adults are prioritizing leisure, particularly travel, to enhance their post-retirement lifestyle. This generation increasingly allocates resources to experiences, favoring quality and convenience. As a result, there is a strong market for guided tours, cruises, and premium accommodations tailored to this age group. Their willingness to pay for safety, comfort, and personalized service has prompted travel providers to develop curated offerings that meet the expectations of this financially stable and travel-enthusiastic demographic. Key Market Challenges: Health and Mobility Concerns Despite improved longevity, health and mobility issues remain significant barriers for senior travelers. Conditions such as chronic illnesses, limited stamina, and the need for continuous medication can restrict travel options. Long journeys, unfamiliar environments, and physically demanding activities may pose challenges and risks, especially in destinations with inadequate healthcare access or senior-friendly infrastructure. Emergencies abroad can be daunting due to language barriers and unfamiliar medical systems. Additionally, travel insurance becomes more costly or limited for seniors, particularly those with pre-existing conditions. Mobility concerns are compounded in areas lacking elevators, ramps, or accessible public transit. These limitations necessitate that travel providers design itineraries and services that account for medical needs, offer accessible facilities, and provide emergency support to ensure a safe and enjoyable travel experience. Key Market Trends: Rise of Wellness and Health-Focused Travel A prominent trend in the Golden Generation Travel Market is the rising interest in wellness-focused and health-enhancing travel experiences. Seniors increasingly seek out destinations and activities that contribute to physical and mental well-being. Wellness retreats, spa getaways, yoga workshops, and nutrition-centered holidays are becoming more popular. Nature-rich locations, therapeutic hot springs, and holistic resorts attract older travelers aiming to rejuvenate and sustain healthy routines. Medical tourism is also gaining momentum, with seniors combining affordable treatments like dental care or orthopedic procedures with leisurely travel. This trend reflects a dual focus on health and exploration. As wellness travel grows, industry players are responding with specialized packages, senior-accessible programs, and health consultations to meet evolving preferences for active, mindful, and restorative travel experiences. Key Market Players American Express Global Business Travel Tripadvisor Airbnb TUI Group Booking Holdings Hilton Worldwide Holdings Expedia Group Wendy Wu Tours Intrepid Group Travel Leaders Group Key Attributes: Report Attribute Details No. of Pages 187 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $8.74 Billion Forecasted Market Value (USD) by 2030 $14.84 Billion Compound Annual Growth Rate 9.2% Regions Covered Global Report Scope: In this report, the global Golden Generation Travel Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Golden Generation Travel Market, By Type: Leisure Travel Adventure Travel Medical Travel Others Golden Generation Travel Market, By Travel Accommodation: Luxury Hotels Budget Hotels Vacation Rentals Hostels Golden Generation Travel Market, By Travel Package: All-Inclusive Packages Customizable Packages Group Travel Packages Last-Minute Deals Golden Generation Travel Market, By Region: North America United States Canada Mexico Europe France Germany Spain Italy United Kingdom Asia-Pacific China Japan India Vietnam South Korea Middle East & Africa South Africa Saudi Arabia UAE Turkey Kuwait Egypt South America Brazil Argentina Colombia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Golden Generation Travel Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Healthcare Cold Chain Logistics Global Report 2025: Expansion of Cold Chain Infrastructure in Emerging Markets to Support Global Vaccine Distribution
Opportunities in healthcare cold chain logistics include the rise in demand for biologics and personalized medicines, driven by technological advancements like real-time monitoring, smart packaging, IoT, and blockchain, which enhance supply chain reliability and regulatory compliance. Expansion into emerging markets and global health initiatives further fuel growth. Healthcare Cold Chain Logistics Market Dublin, July 01, 2025 (GLOBE NEWSWIRE) -- The "Healthcare Cold Chain Logistics - Global Strategic Business Report" has been added to global market for Healthcare Cold Chain Logistics was estimated at US$18.9 Billion in 2024 and is projected to reach US$23.8 Billion by 2030, growing at a CAGR of 3.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Healthcare Cold Chain Logistics market. What Factors Are Driving the Growth of the Healthcare Cold Chain Logistics Market?Several key factors are driving the rapid growth of the healthcare cold chain logistics market, including the increasing demand for biologics and personalized medicines, the rise of global vaccination campaigns, advancements in cold chain technologies, and the expansion of pharmaceutical supply chains into emerging markets. One of the primary drivers is the growing demand for biologics and personalized medicines, which are highly sensitive to temperature variations and require precise storage conditions. Biologics, such as monoclonal antibodies, cell therapies, and gene therapies, represent a significant portion of new drug approvals, and their use is expected to continue rising. The need for specialized cold chain logistics to transport and store these products is fueling the growth of the rise of global vaccination campaigns is another significant factor contributing to the expansion of healthcare cold chain logistics. The COVID-19 pandemic highlighted the importance of an efficient and reliable cold chain for distributing vaccines on a global scale. Many COVID-19 vaccines, including mRNA vaccines, require ultra-low temperature storage, making cold chain logistics essential for their safe distribution. As global health organizations and governments continue to implement large-scale vaccination campaigns, the demand for cold chain logistics solutions that can ensure the safe transport of vaccines to all parts of the world, including remote regions, is expected to in cold chain technologies, such as real-time monitoring systems, smart packaging, and IoT-enabled sensors, are also driving the growth of the market. These innovations make it easier for healthcare providers to track and maintain temperature-sensitive products throughout the supply chain. Real-time data logging and alerts enable organizations to quickly address any issues that arise during transportation or storage, reducing the risk of product spoilage. The growing adoption of these advanced technologies is improving the efficiency and reliability of cold chain logistics, making it an increasingly attractive solution for pharmaceutical companies and healthcare expansion of pharmaceutical supply chains into emerging markets is another key driver of growth in the healthcare cold chain logistics sector. As pharmaceutical companies seek to reach new markets in developing regions, they face the challenge of transporting temperature-sensitive products across long distances, often through regions with inadequate infrastructure. Cold chain logistics providers are expanding their networks and capabilities to ensure that these products can reach their destination without compromising quality or safety. The demand for cold chain solutions that can navigate complex international logistics environments is expected to increase as pharmaceutical companies continue to grow their presence in emerging pressure is also contributing to the growth of the healthcare cold chain logistics market. As regulatory agencies around the world tighten guidelines for the storage and transportation of temperature-sensitive products, healthcare organizations must invest in cold chain systems that can meet these stringent requirements. Regulatory compliance is essential not only for ensuring patient safety but also for avoiding fines, penalties, or product recalls. The need to comply with evolving regulations is prompting healthcare providers and pharmaceutical companies to adopt more advanced and reliable cold chain logistics conclusion, the growth of the healthcare cold chain logistics market is driven by increasing demand for biologics, global vaccination campaigns, advancements in cold chain technologies, and the expansion of pharmaceutical supply chains into emerging markets. As healthcare organizations face the growing challenge of maintaining the integrity of temperature-sensitive products, cold chain logistics will play an essential role in ensuring product safety, regulatory compliance, and effective patient OF STUDY:The report analyzes the Healthcare Cold Chain Logistics market in terms of units by the following Segments: Segments: Product Type (Vaccines, Clinical Trial Materials, Biopharmaceuticals); Segment (Transportation, Packaging, Instrumentation) This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes: Report Attribute Details No. of Pages 274 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $18.9 Billion Forecasted Market Value (USD) by 2030 $23.8 Billion Compound Annual Growth Rate 3.9% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Global Economic Update Healthcare Cold Chain Logistics - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Growing Demand for Temperature-sensitive Pharmaceuticals Drives Growth in Healthcare Cold Chain Logistics Expansion of Biologics, Vaccines, and Biosimilars Fuels Demand for Cold Chain Solutions Role of Cold Chain Logistics in Ensuring Drug Safety and Efficacy Throughout Distribution Technological Advancements in IoT and Sensor-based Monitoring Enhance Cold Chain Logistics Role of Cold Chain Logistics in Reducing Pharmaceutical Waste and Expiry Expansion of Cold Chain Infrastructure in Emerging Markets to Support Global Vaccine Distribution Role of Blockchain in Enhancing Transparency and Traceability in Healthcare Cold Chain Logistics FOCUS ON SELECT PLAYERS Some of the 44 companies featured in this Healthcare Cold Chain Logistics market report include: American Airlines, Inc. AmerisourceBergen Corporation Cavalier Logistics Continental Carbon Company DB Schenker DHL International GmbH FedEx Corporation Kuehne + Nagel International AG Marken Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Healthcare Cold Chain Logistics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ('Advanz Pharma'), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol). 'Our biosimilar candidate is the only one referencing Cimzia® that is under development globally and the reference product has carved out significant market share as treatment for chronic rheumatic diseases, especially for women of childbearing age. I'm very pleased to add it to our expanding commercial partnership with Advanz Pharma,' said Róbert Wessman, Chairman and CEO of Alvotech. 'This agreement further strengthens our strategic partnership with Alvotech and supports our goal to expand access to high-quality biologics for patients in Europe. A proposed biosimilar to Cimzia® is a valuable addition to our sizable biosimilars pipeline,' said Steffen Wagner, CEO of Advanz pegol is a TNF-alpha inhibitor indicated for a variety of inflammatory diseases. Worldwide sales of Cimzia® in 2024 were US$2.3 billion [1].Alvotech and Advanz Pharma have previously entered into partnership agreements for biosimilar candidates to more than ten reference biologics. The companies expect to launch their first biosimilars in Europe in Q4 2025. Use of trademarksCimzia® is a registered trademark of UCB Pharma S.A. Sources[1] Global Data About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. About Advanz PharmaPartner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma's product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding its ability to satisfy conditions precedent to close the transaction and draw down the loan, to comply with the covenants of the Facility and to exercise its rights under the facility, the expected use of proceeds from the Facility, potential future financings or strategic transactions, Alvotech's competitive advantages, business prospects and opportunities including product launches, pipeline product development, revenue and diversification, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of revenue, expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (8) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (9) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (10) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (11) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (12) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (13) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (14) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (15) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; (16) Alvotech's ability to meet the conditions precedent to close Facility and comply with the covenants of the Facility and (17) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. Advanz Pharma Forward Looking StatementsCertain statements in this press release are forward-looking statements. These statements may be identified by words such as 'anticipate', "expectation", "belief', "estimate", "plan", "target', 'project', 'will', 'may', 'should' or "forecast" and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma's markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. MEDIA CONTACTSAlvotech Global Communications and Investor RelationsBenedikt Advanz Pharma Global Corporate CommunicationsCourtney
